Celyad Oncology announces the first patient dosed in

  • KEYNOTE-B79 Phase 1b Trial to Evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in Patients with Stable Microsatellite Metastatic Colorectal Cancer (mCRC) (MSS)
  • ASCO-GI Conference Summary Accepted Highlighting KEYNOTE-B79 Clinical Trial Design

MONT-SAINT-GUIBERT, Belgium, December 16, 2021 (GLOBE NEWSWIRE) – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of therapies T cell antigenics (CAR T) for cancer, today announced that the first patient has received a dose in the KEYNOTE-B79 phase 1b trial (NCT04991948).

The KEYNOTE-B79 assay is part of a collaboration with MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary. The trial will assess the Company’s lead development candidate, its experimental NKG2D CAR T allogeneic cell therapy based on the TCR inhibitor molecule (TIM) CYAD-101, together with MSD’s anti-PD-1 therapy, KEYTRUDA® ( pembrolizumab), in patients with refractory colorectal cancer (mCRC) metastases with stable microsatellite disease (MSS) / mismatch repair.

“Dosing to the first patient in this Phase 1b trial represents an important step towards understanding any potential role of CYAD-101 for mCRC patients with a history of SMS,” said Dr. Charles Morris, medical director of Celyad Oncology. “We are evaluating CYAD-101 in combination with KEYTRUDA in hopes of identifying a new option to target patient tumors. Preclinical and translational data from our previous Phase 1 study of CYAD-101 suggests that there may be additional benefit with pembrolizumab as an anti-PD-1 checkpoint inhibitor when used. associated with CYAD-101 in colorectal cancer and we look forward to studying this in the clinic. We are grateful to MSD for collaborating with us on this trial and plan to share preliminary data next year. “

The company also announced that the KEYNOTE-B79 study will be the subject of a presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium to be held in person in San Francisco, California and virtually from January 20 to 22, 2022.

ASCO GI 2022 Presentation Details:

The following summary will be available on the ASCO GI website on January 18, 2022 at 5:00 p.m. EST. After the presentation at the meeting, the poster will be available in the Scientific Publications section of the Celyad Oncology website.

Abstract number: TPS227
Abstract title: KEYNOTE-B79 phase 1b trial to evaluate allogeneic CAR T cells CYAD-101 and pembrolizumab in patients with refractory metastatic colorectal cancer.
Information about the session: Ongoing Trials Poster Session C: Colon, Rectal and Anal Cancers

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric T (CAR T) antigen therapies for cancer. The Company is developing a pipeline of candidates for allogeneic (ready-to-use) and autologous (personalized) CAR T cell therapy for the treatment of hematologic malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit https://celyad.com/.

Forward-looking statement
This press release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the KEYNOTE-B79 Phase 1b trial, the results of the collaboration with MSD and the safety and tolerability of CYAD-101 in combination with pembrolizumab, forward-looking statements may involve known and unknown risks and uncertainties which could cause actual results, financial condition, performance to occur. or Celyad Oncology’s accomplishments differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include those risks, uncertainties and other risks may be found in the filings and reports of the Securities and Exchange Commission (SEC) of Celyad Oncology, including in its annual report on Form 20-F filed with the SEC on March 25, 2021 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and actual results of Celyad Oncology may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations in this regard or any change in the events, conditions or circumstances upon which such statement is based, except as required by law. law or regulation.

Investor and media contacts:

Sara zelkovic
Communication & Investor Relations Director
Celyad Oncology
[email protected]

Daniel Ferry
General manager
LifeSci Advisors, LLC
[email protected]

Source: Celyad Oncologie SA

Comments are closed.